(Note: For PDF File Swipe To The End Of Article)
Introduction
Hyperkalemia is a potentially life-threatening electrolyte disorder characterized by an abnormally elevated concentration of potassium in the blood. Potassium is one of the most important electrolytes in the human body and is essential for maintaining the resting membrane potential of cells, especially cardiac and skeletal muscle cells. Under normal circumstances, most of the body's potassium is located inside cells, while only a small proportion circulates in the extracellular fluid. Because cardiac electrical activity is highly dependent on the potassium gradient across the cell membrane, even relatively rapid changes in serum potassium can produce significant abnormalities in cardiac conduction and rhythm.
Hyperkalemia is commonly associated with impaired renal potassium excretion, particularly in patients with acute kidney injury or chronic kidney disease. However, kidney dysfunction is not the only cause. Medications that interfere with the renin–angiotensin–aldosterone system, potassium-sparing diuretics, adrenal insufficiency, metabolic acidosis, tissue breakdown, uncontrolled diabetes, excessive potassium administration, and several other conditions may contribute. In many patients, hyperkalemia develops because several risk factors occur simultaneously rather than because of a single isolated cause.
The clinical importance of hyperkalemia lies not simply in the numerical potassium concentration but in its effect on excitable tissues. Mild elevations may produce no symptoms at all, whereas rapidly developing or severe hyperkalemia can cause muscle weakness, paralysis, conduction abnormalities, ventricular arrhythmias, ventricular fibrillation, or cardiac arrest. Importantly, the relationship between serum potassium concentration and ECG abnormalities is not perfectly predictable. Some patients with markedly elevated potassium may have relatively subtle ECG findings, while others can develop dangerous electrical abnormalities at lower concentrations.
For medical students and healthcare professionals, hyperkalemia should therefore be regarded as both a biochemical abnormality and a cardiac emergency when severe or associated with ECG changes. Prompt recognition, confirmation when appropriate, cardiac assessment, identification of the underlying cause, and timely treatment are essential.
Definition of Hyperkalemia
Hyperkalemia refers to an elevation of serum potassium above the normal reference range. The precise upper limit varies slightly between laboratories, but a serum potassium concentration above approximately 5.0–5.5 mmol/L is generally considered abnormal. Merck Manual describes hyperkalemia as a serum potassium concentration above 5.5 mmol/L.
For practical clinical assessment, hyperkalemia is commonly categorized according to serum potassium concentration. A frequently used framework considers potassium around 5.5–5.9 mmol/L as mild hyperkalemia, 6.0–6.4 mmol/L as moderate hyperkalemia, and ≥6.5 mmol/L as severe hyperkalemia. These numerical categories are useful for communication and treatment planning, but they should never replace clinical assessment because the speed of potassium rise, kidney function, symptoms, ECG findings, and associated illness all influence the urgency of treatment. The 2023 UK Kidney Association guideline specifically uses ≥6.5 mmol/L as severe hyperkalemia requiring emergency consideration.
Hyperkalemia can result from either excessive potassium entering the extracellular compartment or inadequate removal of potassium from the body. The kidneys are the principal organs responsible for long-term potassium balance. Consequently, impaired renal function is one of the most important predisposing factors.
Normal Potassium Physiology
Potassium is the major intracellular cation. Approximately 98% of total body potassium is located within cells, while only about 2% is present in extracellular fluid. This unequal distribution is maintained primarily by the sodium-potassium ATPase pump, which actively transports potassium into cells while transporting sodium out.
The concentration gradient between intracellular and extracellular potassium is fundamental to the resting membrane potential of excitable cells. Changes in extracellular potassium therefore influence the electrical behavior of skeletal muscle, smooth muscle, and cardiac tissue.
After dietary potassium is absorbed from the gastrointestinal tract, potassium initially enters the extracellular compartment. Insulin and catecholamines stimulate cellular uptake of potassium, limiting the immediate rise in serum potassium following a meal. The kidneys then regulate potassium elimination, with aldosterone playing a major role in promoting potassium secretion in the distal nephron.
When potassium intake exceeds the ability of the kidneys to excrete potassium, or when potassium shifts from cells into the extracellular space, serum potassium rises. The consequences become particularly dangerous when the increase is rapid.
Classification and Severity
Hyperkalemia can be classified according to biochemical severity as well as clinical significance.
Mild hyperkalemia generally refers to potassium concentrations approximately 5.5–5.9 mmol/L. Patients are often asymptomatic, and ECG findings may be absent. Management usually focuses on identifying reversible causes, reviewing medications, repeating the measurement when appropriate, and preventing further potassium accumulation.
Moderate hyperkalemia generally corresponds to approximately 6.0–6.4 mmol/L. This level requires prompt clinical attention because the risk of cardiac complications becomes more significant. ECG assessment and evaluation for underlying renal or metabolic abnormalities are important.
Severe hyperkalemia is commonly defined as potassium ≥6.5 mmol/L. This is a medical emergency because severe hyperkalemia can produce life-threatening cardiac conduction abnormalities and malignant arrhythmias. The UK Kidney Association recommends emergency assessment and treatment strategies for severe hyperkalemia.
The severity classification should not be interpreted rigidly. A rapidly rising potassium level may be dangerous even before it reaches a traditionally defined severe range. Similarly, significant ECG changes can warrant emergency treatment regardless of the exact potassium concentration.
Causes and Risk Factors
The causes of hyperkalemia can be divided into three broad mechanisms: decreased potassium excretion, excessive potassium administration or intake, and movement of potassium from the intracellular compartment into the extracellular compartment.
Reduced Renal Potassium Excretion
Impaired kidney function is the most important cause of clinically significant hyperkalemia. The kidneys normally excrete excess potassium through the distal nephron. When glomerular filtration and distal potassium secretion are reduced, potassium accumulates in the blood.
Acute kidney injury can cause a rapid increase in serum potassium, particularly when accompanied by oliguria or anuria. Chronic kidney disease can also produce persistent hyperkalemia, especially in advanced stages.
Patients with chronic kidney disease may be particularly vulnerable when another factor is superimposed, such as dehydration, infection, acute kidney injury, medication changes, or excessive potassium intake.
Urinary tract obstruction can also impair potassium excretion. In a patient with unexplained hyperkalemia and kidney dysfunction, obstructive uropathy should therefore be considered when clinically appropriate.
Hypoaldosteronism
Aldosterone promotes sodium reabsorption and potassium secretion in the distal nephron. Reduced aldosterone production or impaired aldosterone activity can therefore lead to potassium retention.
Hypoaldosteronism may occur in adrenal disorders, certain forms of diabetic kidney disease, and other conditions affecting the renin–angiotensin–aldosterone system.
Medications
Several commonly prescribed medications can increase serum potassium.
Important examples include ACE inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists such as spironolactone and eplerenone, potassium-sparing diuretics such as amiloride and triamterene, and some other drugs that interfere with renal potassium handling.
Nonsteroidal anti-inflammatory drugs can contribute by reducing renal prostaglandin synthesis and impairing renin release. Trimethoprim can also promote potassium retention by reducing distal sodium reabsorption in a manner similar to potassium-sparing diuretics.
The risk is substantially increased when several potassium-retaining drugs are combined or when these medications are used in a patient with impaired renal function.
Excessive Potassium Intake
Dietary potassium alone rarely produces severe hyperkalemia in individuals with normally functioning kidneys. However, high potassium intake can become clinically important when renal excretion is impaired.
Potassium supplements, potassium-containing salt substitutes, intravenous potassium administration, and potassium-containing nutritional preparations can all contribute. Excessive intake becomes particularly dangerous when combined with renal failure or medications that impair potassium excretion.
Transcellular Shift of Potassium
Potassium may move from inside cells into the extracellular compartment. This can occur in metabolic acidosis, although the relationship depends on the type and cause of acidosis.
Insulin deficiency, particularly in diabetic ketoacidosis, can promote extracellular potassium accumulation. Despite the high serum potassium, total body potassium in diabetic ketoacidosis is often depleted because of urinary potassium losses.
Cellular destruction can also release large quantities of intracellular potassium. Important examples include rhabdomyolysis, severe burns, crush injuries, tumor lysis, and extensive tissue injury.
Adrenal Insufficiency
Adrenal insufficiency can cause hyperkalemia because aldosterone deficiency reduces renal potassium secretion. Patients may also have hypotension, hyponatremia, weakness, gastrointestinal symptoms, and other features depending on the underlying condition.
Exercise
Strenuous or prolonged exercise can transiently increase extracellular potassium because potassium is released from actively contracting skeletal muscles. In healthy individuals this is normally rapidly corrected by cellular uptake and renal regulation.
Blood Transfusion
Stored blood contains potassium that can accumulate during storage. Large-volume or rapid transfusion can therefore contribute to hyperkalemia, particularly in critically ill patients or patients with impaired renal function.
Pathophysiology of Hyperkalemia
The pathophysiology of hyperkalemia is closely related to the role of potassium in maintaining the resting membrane potential.
Normally, the intracellular potassium concentration is much higher than the extracellular concentration. This concentration gradient contributes to the negative resting membrane potential of excitable cells.
When extracellular potassium rises, the potassium concentration gradient across the cell membrane decreases. Initially, this causes partial depolarization of the resting membrane potential.
At first, mild depolarization can increase membrane excitability. However, persistent or severe depolarization causes voltage-gated sodium channels to remain in an inactivated state. As a result, the ability of cardiac and skeletal muscle cells to generate and conduct electrical impulses becomes progressively impaired.
This explains why hyperkalemia initially produces characteristic ECG changes and, with increasing severity, can cause conduction slowing, loss of atrial activity, QRS widening, ventricular arrhythmias, and ultimately cardiac arrest.
In skeletal muscle, impaired membrane excitability can manifest as weakness. Severe cases may produce flaccid paralysis, although this is less common than asymptomatic disease or cardiac manifestations.
The speed of potassium elevation is also important. A rapidly increasing potassium concentration may produce severe manifestations before the body has had time to compensate. Chronic hyperkalemia may sometimes be better tolerated, although it remains clinically important.
Clinical Features
The clinical manifestations of hyperkalemia are variable. Many patients have no symptoms, particularly when the elevation is mild or develops gradually. Hyperkalemia is frequently discovered incidentally during routine laboratory testing or during evaluation of kidney disease.
When symptoms occur, they are primarily neuromuscular and cardiovascular.
Neuromuscular Manifestations
Patients may develop generalized muscle weakness, heaviness of the limbs, fatigue, paresthesia, or abnormal sensations. Weakness may begin in the lower extremities and progress upward in severe cases.
Rarely, severe hyperkalemia can produce flaccid paralysis. Hyperkalemic periodic paralysis is a separate inherited disorder characterized by episodic muscle weakness associated with potassium shifts.
Cardiovascular Manifestations
The cardiovascular system is the major concern in severe hyperkalemia. Patients may experience palpitations, dizziness, syncope, chest discomfort, or symptoms related to reduced cardiac output.
However, patients with dangerous hyperkalemia may also be completely asymptomatic until a sudden arrhythmia occurs. This is why ECG assessment is crucial in clinically significant hyperkalemia.
Potential cardiac consequences include bradycardia, atrioventricular conduction abnormalities, ventricular arrhythmias, ventricular fibrillation, and asystole.
Gastrointestinal Manifestations
Some patients may experience nausea, vomiting, abdominal discomfort, or other nonspecific symptoms, although these manifestations are not specific to hyperkalemia and may instead reflect the underlying disease.
Signs of Hyperkalemia
Physical findings may be absent in mild cases. When clinical manifestations develop, important findings can include generalized muscle weakness, reduced muscle strength, abnormal cardiac rhythm, bradycardia, hypotension, or signs of the underlying cause.
A careful physical examination should assess hydration and volume status, cardiac rhythm, neuromuscular function, evidence of tissue injury, and features suggesting renal, endocrine, metabolic, or medication-related causes.
Because physical examination cannot reliably determine the severity of hyperkalemia, laboratory measurement and ECG assessment remain essential.
ECG Changes in Hyperkalemia
The ECG is one of the most important investigations in significant hyperkalemia because elevated potassium can directly affect cardiac conduction.
The classic progression begins with tall, narrow, symmetrical peaked T waves. As potassium rises further, the QT interval may shorten, followed by PR prolongation and progressive slowing of conduction.
With more severe hyperkalemia, the P waves may become flattened and eventually disappear, while the QRS complex widens. Further progression can produce fusion of the widened QRS complex with the T wave, producing a characteristic sine-wave appearance.
Eventually, severe conduction disturbance can progress to ventricular fibrillation, ventricular standstill, or asystole.
Importantly, ECG findings do not always correlate predictably with serum potassium. A normal ECG does not guarantee that severe hyperkalemia is harmless. Conversely, significant ECG abnormalities can justify emergency treatment even while laboratory confirmation is being repeated.
For this reason, patients with clinically important hyperkalemia should undergo appropriate ECG assessment and cardiac monitoring.
Diagnosis
The diagnosis of hyperkalemia is established by measuring serum potassium. However, diagnosis should not stop at identifying the abnormal laboratory value. The clinician must determine whether the result is genuine, assess its severity, identify complications, and investigate the underlying cause.
The initial assessment should include a detailed history, medication review, physical examination, serum electrolytes, renal function tests, glucose measurement, acid–base assessment when indicated, and ECG.
The UK Kidney Association emphasizes structured emergency assessment, including ABCDE assessment, ECG evaluation, potassium measurement, and identification of the underlying cause.
Pseudohyperkalemia
Pseudohyperkalemia is an important diagnostic consideration because an artificially elevated serum potassium can lead to unnecessary treatment.
It usually occurs because potassium is released from blood cells during or after collection. Hemolysis is a common cause. Difficult venipuncture, prolonged tourniquet application, excessive fist clenching, traumatic sampling, or delayed processing can contribute.
Pseudohyperkalemia should be suspected when the laboratory result is unexpectedly high and does not fit the patient's clinical picture, particularly when there are no risk factors or ECG abnormalities.
If pseudohyperkalemia is suspected, the potassium measurement should be repeated using appropriate sampling technique and the laboratory should be informed when necessary.
Laboratory Investigations
Serum electrolytes are fundamental. Potassium should be interpreted alongside sodium, chloride, bicarbonate, and other relevant biochemical parameters.
Renal function should be assessed using serum creatinine and appropriate estimates of kidney function. Urea may also provide useful information about renal impairment and the overall clinical state.
Blood glucose is important because insulin deficiency and hyperglycemic emergencies can contribute to potassium elevation.
Serum bicarbonate or blood gas analysis may identify metabolic acidosis, which can contribute to extracellular potassium movement.
Additional investigations depend on the suspected cause. Creatine kinase may be appropriate when rhabdomyolysis is suspected. Urinalysis and renal imaging may be considered when kidney disease or urinary obstruction is suspected.
A medication review is essential because several commonly used drugs can contribute to hyperkalemia.
Assessment of the Underlying Cause
Once hyperkalemia has been confirmed, the clinician should ask several questions.
Is kidney function impaired?
Has there been recent acute illness, dehydration, infection, or hypotension?
Is the patient taking ACE inhibitors, ARBs, spironolactone, eplerenone, potassium-sparing diuretics, NSAIDs, trimethoprim, potassium supplements, or other potassium-retaining medications?
Is there evidence of metabolic acidosis or diabetic ketoacidosis?
Has there been tissue injury, rhabdomyolysis, burns, crush injury, or tumor lysis?
Could adrenal insufficiency or hypoaldosteronism be present?
Could the laboratory result represent pseudohyperkalemia?
This systematic approach helps prevent the common mistake of treating the potassium value without addressing the process responsible for its elevation.
Treatment Principles
Management depends on the potassium concentration, ECG findings, symptoms, rate of potassium increase, kidney function, and underlying cause.
The major goals are:
- Protect the heart from the effects of hyperkalemia.
- Temporarily shift potassium from the extracellular space into cells.
- Remove potassium from the body.
- Correct the underlying cause.
- Prevent recurrence.
Emergency management is particularly important when potassium is severely elevated or when ECG abnormalities are present.
The KDIGO conference algorithm emphasizes cardiac monitoring and ECG assessment, followed by calcium when indicated, insulin with glucose and/or a beta-2 agonist to shift potassium intracellularly, measures to remove potassium, and consideration of dialysis when appropriate.
Cardiac Stabilization With Intravenous Calcium
Intravenous calcium is used to stabilize the cardiac membrane in patients with significant hyperkalemia and ECG abnormalities.
Calcium does not lower the serum potassium concentration. Its purpose is to temporarily antagonize the adverse electrical effects of hyperkalemia on the myocardium.
The effect begins rapidly but is temporary, so calcium should be considered a bridge while definitive potassium-lowering therapy is initiated.
Calcium gluconate and calcium chloride are both used in emergency practice, with the choice depending on the clinical setting and local protocol. Calcium chloride contains more elemental calcium per volume but is more irritating to peripheral veins and is generally preferentially administered through appropriate venous access.
The UK Kidney Association provides specific recommendations and dosing protocols for emergency calcium administration.
Shifting Potassium Into Cells
The next major therapeutic objective is to temporarily move potassium from the extracellular fluid into cells.
Insulin and Glucose
Intravenous insulin is one of the most effective emergency measures for rapidly lowering serum potassium by promoting cellular potassium uptake.
Because insulin can cause hypoglycemia, glucose is administered alongside it or according to the patient's blood glucose level and local protocol. Blood glucose must be monitored after treatment.
The potassium-lowering effect is temporary because insulin does not remove potassium from the body. It simply shifts potassium into cells. Therefore, insulin–glucose therapy must be combined with measures that ultimately remove potassium when significant hyperkalemia is present.
The UK Kidney Association specifically emphasizes glucose monitoring and additional glucose administration in selected patients to reduce the risk of hypoglycemia.
Nebulized Salbutamol
High-dose nebulized salbutamol, a beta-2 adrenergic agonist, can stimulate cellular potassium uptake.
It is generally used as an adjunct rather than as sole therapy for severe hyperkalemia. The UK Kidney Association recommends nebulized salbutamol as adjunctive therapy in severe hyperkalemia and advises against using it as monotherapy in severe cases.
Not every patient responds equally to beta-2 agonists, and some individuals may have contraindications or clinically significant tachycardia.
Sodium Bicarbonate
Sodium bicarbonate is not routinely recommended as the primary emergency treatment for hyperkalemia. It may have a role in selected patients with significant metabolic acidosis, depending on the clinical circumstances.
The UK Kidney Association recommends against routine intravenous bicarbonate for acute hyperkalemia.
Removing Potassium From the Body
Temporarily shifting potassium into cells does not eliminate the excess potassium. Definitive management requires removal of potassium from the body or correction of the condition causing potassium accumulation.
Diuretics
Loop diuretics can increase urinary potassium excretion in patients who have adequate renal function and sufficient urine production.
They are not reliable in severe kidney failure or anuric patients and should not be used indiscriminately in patients who are volume depleted.
Potassium Binders
Potassium-binding medications remove potassium through the gastrointestinal tract.
Modern potassium binders include sodium zirconium cyclosilicate and patiromer. The UK Kidney Association recommends sodium zirconium cyclosilicate in emergency management of severe hyperkalemia and considers it in moderate hyperkalemia.
These agents should be viewed as part of an overall treatment strategy rather than substitutes for immediate cardiac stabilization in a patient with dangerous ECG abnormalities.
Hemodialysis
Hemodialysis is one of the most effective methods of rapidly removing potassium from the body.
It is particularly important in patients with severe hyperkalemia and advanced kidney failure, especially when potassium remains elevated despite medical therapy, when there is severe renal impairment with inadequate potassium excretion, or when life-threatening complications occur.
The KDIGO emergency algorithm identifies dialysis as an important consideration in patients with acute kidney injury or chronic kidney disease and persistent or severe hyperkalemia.
Emergency Management Approach
When severe hyperkalemia is suspected, management should be organized systematically rather than waiting passively for every laboratory result.
The patient should first undergo assessment of airway, breathing, and circulation. Cardiac monitoring and a 12-lead ECG should be obtained promptly.
If significant ECG abnormalities attributable to hyperkalemia are present, cardiac membrane stabilization with intravenous calcium should be initiated according to the local emergency protocol.
At the same time, potassium should be shifted intracellularly using appropriate therapy such as insulin with glucose, with nebulized salbutamol used as an adjunct when appropriate.
Measures to remove potassium from the body should then be initiated according to the clinical situation. This may include a potassium binder, diuretic therapy in selected patients, or urgent dialysis.
Repeated potassium measurements and glucose monitoring are essential because initial treatment may only produce a temporary reduction in serum potassium.
Management of Mild Hyperkalemia
Mild hyperkalemia without ECG abnormalities generally does not require the same emergency interventions used for severe hyperkalemia.
The first step is to confirm the result when appropriate and investigate reversible causes. The medication list should be carefully reviewed, and potassium supplements or unnecessary potassium-retaining medications may need to be stopped or adjusted by the treating clinician.
Dietary potassium intake should be assessed, particularly in patients with chronic kidney disease. However, dietary restriction should be individualized rather than applied indiscriminately.
Renal function, acid–base status, diabetes control, and other contributing factors should be evaluated.
Follow-up potassium measurement is important to determine whether the abnormality is resolving or progressing.
Management of Chronic Hyperkalemia
Chronic hyperkalemia is commonly encountered in patients with chronic kidney disease, heart failure, diabetes, or treatment with renin–angiotensin–aldosterone system inhibitors.
Long-term management aims to maintain potassium within a safe range while preserving the benefits of medications that may improve cardiovascular or renal outcomes.
The clinician should identify reversible factors such as dehydration, acute kidney injury, inappropriate potassium supplementation, constipation, uncontrolled diabetes, metabolic acidosis, and interacting medications.
Dietary counseling may be required. Potassium binders can be useful in selected patients who develop recurrent hyperkalemia while receiving clinically beneficial therapies.
Management should be individualized because unnecessarily discontinuing evidence-based cardiovascular or renal medications can also have important consequences.
Dietary Considerations
Dietary potassium restriction can be useful in selected patients, particularly those with chronic kidney disease and recurrent hyperkalemia.
Foods naturally rich in potassium include bananas, potatoes, tomatoes, beans, dried fruits, many leafy vegetables, and several other fruits and vegetables. However, the nutritional value of these foods means that broad dietary restriction without professional guidance may be inappropriate.
The objective is not simply to eliminate all potassium-containing foods. Instead, dietary management should consider the patient's total potassium intake, kidney function, medication profile, food preparation methods, and recurrence of hyperkalemia.
Patients should also be warned about potassium-containing salt substitutes because many products replace sodium chloride with potassium chloride.
Medication Review and Prevention
Medication review is one of the most important components of preventing recurrent hyperkalemia.
Drugs that may increase potassium should be assessed individually rather than automatically discontinued. The clinician should consider the indication, dose, kidney function, serum potassium, and availability of alternative strategies.
Particular attention should be paid to combinations of ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, potassium-sparing diuretics, NSAIDs, and other medications affecting potassium homeostasis.
Patients with chronic kidney disease may require periodic potassium and renal function monitoring, especially after medication initiation or dose changes.
Hyperkalemia in Chronic Kidney Disease
Chronic kidney disease substantially increases the risk of hyperkalemia because the ability of the kidneys to excrete potassium is reduced.
The risk becomes particularly important in advanced chronic kidney disease and when other factors are present, including diabetes, metabolic acidosis, high potassium intake, acute illness, and potassium-retaining medications.
However, chronic kidney disease does not mean that all renin–angiotensin–aldosterone system inhibitors must automatically be discontinued. These medications may provide important renal and cardiovascular benefits, so the approach should involve careful monitoring and management of hyperkalemia rather than reflexive discontinuation whenever possible.
In severe or refractory cases, renal replacement therapy may be necessary.
Hyperkalemia in Acute Kidney Injury
Acute kidney injury can cause a rapid accumulation of potassium because renal filtration and potassium excretion may suddenly decrease.
The risk is particularly high in oliguric or anuric patients. Additional contributors such as metabolic acidosis, tissue injury, medications, and potassium administration can accelerate the rise.
Patients with acute kidney injury and significant hyperkalemia require close biochemical and cardiac monitoring.
When medical therapy fails to control potassium or when life-threatening complications are present, urgent renal replacement therapy may be required.
Hyperkalemia in Diabetic Ketoacidosis
Hyperkalemia is common at presentation in diabetic ketoacidosis despite the fact that total body potassium is usually depleted.
Insulin deficiency, hyperosmolality, and acid–base disturbances promote movement of potassium from cells into the extracellular space. At the same time, osmotic diuresis causes substantial urinary potassium loss.
Once insulin therapy is initiated, potassium begins to move back into cells and serum potassium may fall rapidly. Therefore, potassium must be monitored closely during treatment.
This illustrates an important principle: serum potassium does not always reflect total body potassium stores.
Hyperkalemia and Metabolic Acidosis
Metabolic acidosis can contribute to extracellular potassium accumulation, although the relationship varies depending on the underlying type of acidosis.
Organic acidosis, such as lactic acidosis or ketoacidosis, does not necessarily produce the same potassium shift as mineral acid accumulation. Insulin deficiency and tissue metabolism may play major roles in some clinical situations.
Correcting the underlying cause of acidosis is therefore more important than routinely administering bicarbonate solely to lower potassium.
Hyperkalemia Due to Tissue Breakdown
Large-scale tissue injury can release intracellular potassium into the bloodstream.
Rhabdomyolysis is an important example. It can occur following trauma, prolonged immobilization, seizures, extreme physical exertion, ischemia, certain medications or toxins, and other conditions.
Tumor lysis syndrome can also produce hyperkalemia because rapid destruction of malignant cells releases intracellular potassium along with phosphate and nucleic acid breakdown products.
In such patients, management must address both the potassium abnormality and the underlying tissue destruction.
Complications
The major complications of hyperkalemia arise from impaired neuromuscular and cardiac electrical activity.
Cardiac complications are the most immediately dangerous. They include conduction slowing, bradyarrhythmias, atrioventricular block, ventricular tachyarrhythmias, ventricular fibrillation, and asystole.
Severe neuromuscular manifestations can include profound muscle weakness and, rarely, paralysis.
A particularly dangerous feature is the possibility of sudden deterioration. A patient who appears relatively stable can develop a malignant arrhythmia if potassium continues to rise.
Hyperkalemia may also complicate the management of other serious conditions, particularly acute kidney injury, chronic kidney disease, diabetic ketoacidosis, adrenal insufficiency, and tissue breakdown.
Prognosis
The prognosis of hyperkalemia depends on its cause, severity, speed of development, associated illness, kidney function, and whether cardiac complications have occurred.
Mild hyperkalemia caused by a reversible medication or dietary factor may resolve after correction of the precipitating problem.
Severe hyperkalemia, particularly when associated with ECG abnormalities, renal failure, metabolic disturbances, or ongoing tissue breakdown, carries a substantial risk of morbidity and mortality if treatment is delayed.
Rapid recognition and appropriate emergency management can significantly reduce the risk of catastrophic cardiac complications.
Monitoring During Treatment
Monitoring is essential because many emergency treatments produce temporary changes.
Serum potassium should be reassessed after treatment to determine whether the concentration has fallen adequately and whether rebound hyperkalemia is occurring.
Blood glucose must be monitored carefully following insulin administration because hypoglycemia is an important treatment-related complication.
Continuous cardiac monitoring is appropriate for patients with severe hyperkalemia or significant ECG abnormalities.
Renal function, urine output, acid–base status, fluid balance, and the response to potassium-removing therapies should also be followed.
The UK Kidney Association guideline emphasizes structured monitoring after emergency treatment, including repeated potassium and glucose assessment.
Important Clinical Pearls
Hyperkalemia should always be interpreted in clinical context rather than by potassium concentration alone.
A potassium concentration ≥6.5 mmol/L is generally considered severe and warrants emergency attention.
ECG abnormalities are particularly concerning and require immediate assessment and treatment.
A normal ECG does not completely exclude dangerous hyperkalemia.
Intravenous calcium protects the heart but does not remove potassium.
Insulin with glucose shifts potassium into cells but does not eliminate total body potassium.
Salbutamol can be used as an adjunctive potassium-shifting treatment but should not be relied upon as monotherapy for severe hyperkalemia.
Definitive management requires removal of potassium and treatment of the underlying cause.
Pseudohyperkalemia should be considered when a laboratory result is unexpectedly high and inconsistent with the clinical situation.
Kidney disease is one of the most important risk factors, but medication effects, metabolic disturbances, tissue breakdown, endocrine disorders, and excessive potassium administration can also be responsible.
Most importantly, hyperkalemia is not merely a laboratory abnormality. Severe hyperkalemia can rapidly become a cardiac emergency, making early recognition and structured management essential.
.jpeg)
